Clinical trial
CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic…
NCT00091260 · Vaishali Sanchorawala, Other · Completed
Key facts
| NCT number | NCT00091260 |
|---|---|
| Title | CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis |
| Official title | A Phase II Trial of the Immunomodulatory Drug CC-5013 for Patients With AL Amyloidosis |
| Lead sponsor | Vaishali Sanchorawala, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | dexamethasone, lenalidomide |
| Enrollment | 82 |
| Start date | Jan 1, 2004 |
| Primary completion | Jul 1, 2012 |
| Completion | May 1, 2015 |
| First posted | Sep 9, 2004 |
| Last update posted | Feb 20, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: